PRMT1 and Miyoshi myopathy: PRMT1 enzymatic inhibition can increase the sensitivity of MM cells to proteasome inhibitor bortezomib.[24, 36] In addition, it has been shown that PRMT1‐mediated arginine methylation regulates muscle stem cell fate and epithelial cell stemness.[37, 38] However, the role of PRMT1 in LSCs is largely unknown.